AMPICILLIN

Generic: AMPICILLIN SODIUM

Sandoz IncManufacturer
INTRAMUSCULAR, INTRAVENOUSRoute
AMPICILLIN SODIUMActive Substance
1971-03-03Original Approval

AMPICILLIN is FDA application ANDA061395, sponsored by SANDOZ. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.

Recalls

Top Reported Reactions

1
DRUG INEFFECTIVE
962 reports
2
FOETAL EXPOSURE DURING PREGNANCY
674 reports
3
DRUG HYPERSENSITIVITY
624 reports
4
MATERNAL EXPOSURE DURING PREGNANCY
549 reports
5
PREMATURE BABY
524 reports
6
OFF LABEL USE
495 reports
7
PYREXIA
449 reports
8
ACUTE KIDNEY INJURY
360 reports
9
PREMATURE DELIVERY
345 reports
10
RENAL FAILURE
332 reports